JP2022547231A - 眼疾患の予防および処置のための方法およびＰｎＰＰ－１９の使用 - Google Patents

眼疾患の予防および処置のための方法およびＰｎＰＰ－１９の使用 Download PDF

Info

Publication number
JP2022547231A
JP2022547231A JP2022539453A JP2022539453A JP2022547231A JP 2022547231 A JP2022547231 A JP 2022547231A JP 2022539453 A JP2022539453 A JP 2022539453A JP 2022539453 A JP2022539453 A JP 2022539453A JP 2022547231 A JP2022547231 A JP 2022547231A
Authority
JP
Japan
Prior art keywords
pnpp
eye
glaucoma
ocular
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022539453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547231A5 (enExample
Inventor
シウヴァ クーニャ ジュニオール，アルマンド ダ
リマ ペレス ガルシア，マリア エレナ ジ
ダ シウヴァ，カロリーナ ヌネス
ヌネス ドウラド，ライス フェルナンダ
ボルジェス ダ シウヴァ，ペルラ ヴィラニ
サンパイオ ラカチヴァ，パウロ グスタヴォ
グロス，ゲルハルト マックス
ジ パウラ ジュニオール，アイロン フランシスコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Universidade Federal de Minas Gerais
Original Assignee
Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozeus Desenvolvimento De Produtos Biofarmaceuticos, Universidade Federal de Minas Gerais filed Critical Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Publication of JP2022547231A publication Critical patent/JP2022547231A/ja
Publication of JP2022547231A5 publication Critical patent/JP2022547231A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022539453A 2019-09-03 2020-09-01 眼疾患の予防および処置のための方法およびＰｎＰＰ－１９の使用 Pending JP2022547231A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962895252P 2019-09-03 2019-09-03
US62/895,252 2019-09-03
US17/008,794 US20210060125A1 (en) 2019-09-03 2020-09-01 METHOD AND USE OF PnPP-19 FOR PREVENTING AND TREATING EYE DISEASES
US17/008,794 2020-09-01
PCT/BR2020/050349 WO2021042193A1 (en) 2019-09-03 2020-09-01 Method and use of pnpp-19 for preventing and treating eye diseases

Publications (2)

Publication Number Publication Date
JP2022547231A true JP2022547231A (ja) 2022-11-10
JP2022547231A5 JP2022547231A5 (enExample) 2023-09-01

Family

ID=74682721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539453A Pending JP2022547231A (ja) 2019-09-03 2020-09-01 眼疾患の予防および処置のための方法およびＰｎＰＰ－１９の使用

Country Status (8)

Country Link
US (1) US20210060125A1 (enExample)
EP (1) EP4025234A4 (enExample)
JP (1) JP2022547231A (enExample)
KR (1) KR20220084011A (enExample)
CN (1) CN114302734A (enExample)
BR (1) BR112022003759A2 (enExample)
CA (1) CA3147704A1 (enExample)
WO (1) WO2021042193A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR131863A1 (es) * 2023-02-17 2025-05-07 Biozeus Biopharmaceuticals S A Formulación peptídica tópica para el tratamiento de la disfunción sexual
WO2025133214A1 (en) 2023-12-21 2025-06-26 Novaliq Gmbh Ophthalmic polypeptide compositions for the treatment of posterior eye disorders
CN118985527B (zh) * 2024-09-04 2026-05-01 首都医科大学附属北京同仁医院 一种无须眼部干预的病理性近视动物模型建立方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005097137A (ja) * 2003-09-22 2005-04-14 Tokyoto Igaku Kenkyu Kiko 糖尿病性網膜症の予防又は治療剤
JP2011219412A (ja) * 2010-04-09 2011-11-04 Saisentan Igaku Kenkyusho:Kk 緑内障の視野改善治療薬
JP2015535808A (ja) * 2012-08-20 2015-12-17 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 合成ポリペプチドＰｎＴｘ（１９）、医薬組成物及びその使用
WO2017068388A2 (pt) * 2015-09-18 2017-04-27 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759298B2 (en) * 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
BR102014010268B1 (pt) * 2014-04-29 2021-12-28 Universidade Federal De Minas Gerais - Ufmg Uso do peptídeo sintético pntx-19 para tratamento de dor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005097137A (ja) * 2003-09-22 2005-04-14 Tokyoto Igaku Kenkyu Kiko 糖尿病性網膜症の予防又は治療剤
JP2011219412A (ja) * 2010-04-09 2011-11-04 Saisentan Igaku Kenkyusho:Kk 緑内障の視野改善治療薬
JP2015535808A (ja) * 2012-08-20 2015-12-17 ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー 合成ポリペプチドＰｎＴｘ（１９）、医薬組成物及びその使用
WO2017068388A2 (pt) * 2015-09-18 2017-04-27 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRITISH J PHARMACOL., vol. 173, JPN6024029661, 2016, pages 1491 - 1501, ISSN: 0005380792 *

Also Published As

Publication number Publication date
US20210060125A1 (en) 2021-03-04
BR112022003759A2 (pt) 2022-05-31
CN114302734A (zh) 2022-04-08
KR20220084011A (ko) 2022-06-21
WO2021042193A1 (en) 2021-03-11
EP4025234A4 (en) 2023-09-20
CA3147704A1 (en) 2021-03-11
EP4025234A1 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
US11273197B2 (en) Adiponectin peptidomimetics for treating ocular disorders
US20180296630A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
Li et al. Glaucoma and ocular surface disease: more than meets the eye
US20210060125A1 (en) METHOD AND USE OF PnPP-19 FOR PREVENTING AND TREATING EYE DISEASES
CA3095073A1 (en) Sap and peptidomimetics for treatment of eye disease
CN110869045B (zh) 包含i型胶原及色素上皮衍生因子肽作为有效成分的预防或治疗新生血管性疾病的药物组合物
RU2744878C2 (ru) Ингибиторы дипептидилпептидазы-4 для местного офтальмологического лечения нейродегенеративных заболеваний сетчатки
JP2022505832A (ja) アディポネクチンペプチド模倣組成物
HK40027227A (en) Adiponectin peptidomimetics for treating ocular disorders
JP2020535117A (ja) 眼疾患を治療するためのアディポネクチンペプチド模倣薬
WO2025133214A1 (en) Ophthalmic polypeptide compositions for the treatment of posterior eye disorders
HK1246178B (en) Adiponectin peptidomimetics for treating ocular disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250305